Research Topics
Genomes and Genes | Keiichi EnjyojiSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsivenessNorikatsu Mizumoto
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Nat Med 8:358-65. 2002....
Deletion of cd39/entpd1 results in hepatic insulin resistanceKeiichi Enjyoji
Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Diabetes 57:2311-20. 2008..CD39/ENTPD1 is the dominant vascular and immune cell ectoenzyme that hydrolyzes extracellular nucleotides to regulate purinergic signaling...- Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regenerationGuido Beldi
Transplant and Liver Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts 02215, USA
Gastroenterology 135:1751-60. 2008..We aimed to determine the effects of the vascular ectonucleotidase CD39 on sinusoidal endothelial cell responses following partial hepatectomy and to dissect purinergic and growth factor interactions in this model... - Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitisGuido Beldi
Liver and Transplantation Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Hepatology 48:841-52. 2008..Deletion of CD39 is protective in [corrected] Con A-induced hepatitis. This study illustrates a [corrected] role for purinergic signaling in NKT-mediated mechanisms that result in liver immune injury... - From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel diseaseDavid J Friedman
Renal Division and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard University, 330 Brookline Avenue, Boston, MA 02215, USA
Proc Natl Acad Sci U S A 106:16788-93. 2009..005-0.0006). Our data indicate that CD39 deficiency exacerbates murine colitis and suggest that CD39 polymorphisms are associated with inflammatory bowel disease in humans... - Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in miceGuido Beldi
Department of Medicine and Surgery, Liver Center and Transplantation Institute, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Hepatology 51:1702-11. 2010.... - CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in miceXiaofeng Sun
Department of Medicine, Transplantation Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Gastroenterology 139:1030-40. 2010..In this study, we have examined the effect of CD39 expression by Tregs on effector immune cell responses to hepatic metastases in vivo... 
Variable impact of CD39 in experimental murine colitisBeat M Künzli
Transplant Institute and Gastroenterology Division, Beth Israel Deaconess Medical Centre Harvard Medical School, Harvard University, Boston, MA 02215, USA
Dig Dis Sci 56:1393-403. 2011..Genetic polymorphisms of CD39 have been linked to Crohn's disease while gene deletion in mice exacerbates dextran sodium sulphate-induced colitis...- Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null miceBeat M Künzli
Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA
Gastroenterology 134:292-305. 2008..Because the role of extracellular nucleotides and CD39 in mediating inflammation and fibrosis are understood poorly, we studied the impact of CD39 gene deletion in a model of pancreatic disease... - Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null miceShaun W Jackson
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Am J Pathol 171:1395-404. 2007..Our data indicate novel links between CD39/ENTPD1, extracellular nucleotide-mediated signaling, and vascular endothelial cell integrin function that impact on angiogenesis and tumor growth... - Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal diseaseDavid J Friedman
Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Diabetes 58:999-1006. 2009..The vascular ectonucleotidase ENTPD1 protects against renal injury and modulates glucose homeostasis in mouse models. We sought to determine whether human variation in ENTPD1 influences predisposition to diabetes or diabetic nephropathy... - The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolismGuido Beldi
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA 02215, USA
Front Biosci 13:2588-603. 2008.... - Tob1 is a constitutively expressed repressor of liver regenerationKaren J Ho
Department of Surgery, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Exp Med 207:1197-208. 2010..We provide direct evidence that levels of an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial check point molecule that modulates the expression and activity of cell cycle proteins... - The vascular ectonucleotidase ENTPD1 is a novel renoprotective factor in diabetic nephropathyDavid J Friedman
Renal Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Diabetes 56:2371-9. 2007..We conclude that ENTPD1 is a vascular protective factor in diabetic nephropathy that modulates glomerular inflammation and thromboregulation... - Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targetsBen Atkinson
Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
Blood Cells Mol Dis 36:217-22. 2006..Future clinical applications will involve the development of new therapeutic strategies to various inflammatory vascular diseases and in transplantation... - Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantationSimon C Robson
Vascular Biology and Transplantation Centers, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Research North, 99 Brookline Avenue, Boston, MA 02215, USA
Semin Thromb Hemost 31:217-33. 2005..Administration of soluble CD39 or targeted expression may have future therapeutic application in transplantation-associated and other vascular diseases... - Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancerBeat M Künzli
Liver and Transplantation Centers, Beth Israel Deaconess Medical Center, Harvard University, Boston, USA
Purinergic Signal 7:231-41. 2011..Our studies also suggest potential roles for purinergic-based therapies in clinical CRC... - Liver damage and systemic inflammatory responses are exacerbated by the genetic deletion of CD39 in total hepatic ischemiaXiaofeng Sun
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 3, Blackfan Circle, Boston, MA, 02115, USA
Purinergic Signal 7:427-34. 2011..We conclude that CD39 is protective in hepatic IRI preventing local injury and systemic inflammation in an adenosine dependent manner. Our data indicate that vascular CD39 expression has an essential protective role in hepatic IRI... - Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptorsHolger K Eltzschig
Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
J Exp Med 198:783-96. 2003..Taken together, these results demonstrate transcription coordination of adenine nucleotide and nucleoside signaling at the vascular interface during hypoxia... - P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell DeathShu Bian
Department of Gastroenterology, Provincial Hospital affiliated to Shandong University, Jinan, People s Republic of China Department of Medicine, Transplant Institute, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 8:e60184. 2013..CONCLUSIONS: Our study defines novel molecular mechanisms underpinning the antitumor actions of P2X7 and provides a further rationale for purine-based drugs in targeted cancer therapy... - Vascular smooth muscle cell expression of ectonucleotidase CD39 (ENTPD1) is required for neointimal formation in miceAmir Behdad
Transplantation Institute and Liver Center, CLS 612, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Purinergic Signal 5:335-42. 2009..Cd39 is the dominant ectonucleotidase expressed by VSMC. Deletion of Cd39 in mice results in decreased neointimal formation after vascular injury and is associated with impaired VSMC migration responses in vitro... - Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasisSassan HajMohammadi
Section of Cardiology, Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire, USA
J Clin Invest 111:989-99. 2003..Instead, 3-OST-1-deficient mice exhibited unanticipated phenotypes suggesting that HS(act) or additional 3-OST-1-derived structures may serve alternate biologic roles... - Tubuloglomerular feedback and renin secretion in NTPDase1/CD39-deficient miceMona Oppermann
National Institute of Digestive and Diabetes and Kidney Diseases, National Institute of Health, 10 Center Drive MSC 1370, Bethesda, MD 20892, USA
Am J Physiol Renal Physiol 294:F965-70. 2008.... - The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migrationKatrin Färber
Cellular Neuroscience, Max Delbruck Center for Molecular Medicine, Berlin, Germany
Glia 56:331-41. 2008..We conclude that the co-stimulation of purinergic and adenosine receptors is a requirement for microglial migration and that the expression of cd39 controls the ATP/adenosine balance... - Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injuryOlaf Guckelberger
Department of Visceral and Transplantation Surgery, Charite Campus Virchow Clinic, Humboldt University, Berlin, Germany
Thromb Haemost 91:576-86. 2004..The potential of NTPDases to maintain vascular integrity suggests potential pharmacological benefit of these agents in mesenteric ischemic injury... - Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteriesXinhua Yin
Department of Pathology, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita City, Osaka, Japan
Cardiovasc Res 56:454-63. 2002....